JOSEPH CROWLEY: Open Payments
NPI 1093330375 · GLENDALE, CO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,906 in 103 payments from 15 companies in 2025. Trend: 2023 $2,898 · 2024 $4,905 · 2025 $2,906
Food & beverage: $2,805Education: $101
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 14 | $467 |
| ABBVIE INC. | 18 | $465 |
| Teva Pharmaceuticals USA, Inc. | 10 | $451 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 10 | $342 |
| Lundbeck LLC | 11 | $190 |
| E.R. Squibb & Sons, L.L.C. | 6 | $182 |
| Otsuka America Pharmaceutical, Inc. | 8 | $178 |
| Vanda Pharmaceuticals Inc. | 6 | $137 |
| Collegium Pharmaceutical, Inc. | 7 | $124 |
| Tris Pharma Inc | 4 | $117 |
Products named: VRAYLAR, REXULTI, CAPLYTA, UZEDY, ARISTADA, COBENFY, LYBALVI, FANAPT.
Industry payments across CO — which companies pay providers there.
